NRX Pharmaceuticals Q3 2026 Results: Net Loss of $2.17M, Loss Narrows
NRX Pharmaceuticals reported a net loss of $20.1 million for the nine months ended September 30, 2026, an improvement from the $29.0 million loss in the prior year period. The company significantly increased its cash position to $19.8 million through various equity offerings, while net patient service revenue grew to $3.3 million.
- Key figure
- Net loss $2.17M